<DOC>
	<DOCNO>NCT01452685</DOCNO>
	<brief_summary>The purpose study compare long term safety efficacy TAK-385 , daily ( QD ) follow continue administration participant complete Phase II dose-finding study .</brief_summary>
	<brief_title>A Long-term Extension Study TAK-385 Treatment Endometriosis</brief_title>
	<detailed_description>This study long-term extension study evaluation safety efficacy TAK-385 follow administration 24 week ( calculated Visit 3 TAK-385/CCT-101 study ) participant Phase II dose-finding study ( TAK-385/CCT-101 study ) .</detailed_description>
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>1 . Participants complete TAK385/CCT101 study 1 . Participants adverse event TAK385/CCT101 study make continue administration study drug difficult 2 . Participants become unable comply protocol due onset new disease , symptom , find , aggravation clinical laboratory finding 3 . Participants investigator deem study drug show efficacy base level pain , menstruation status , status analgesic drug intake TAK385/CCT101 study , study continuation represent unacceptable risk 4 . Participants investigator deem study continuation difficult due occurrence low estrogen symptom TAK385/CCT101 study attribute pharmacological effect study drug take account level frequency adverse event etc . well riskbenefit participant .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>